Trial Profile
A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin in Subjects With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Samsung Bioepis
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 26 Sep 2019 Results published in a Samsung Bioepis media release.
- 26 Sep 2019 According to a Samsung Bioepis media release, results will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.